ANAB

AnaptysBio, Inc. [ANAB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ANAB Stock Summary

Top ANAB Correlated Resources

ANAB


Top 10 Correlated ETFs

ANAB


Top 10 Correlated Stocks

ANAB


In the News

06:48 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

02:10 22 Mar 2023 ANAB

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.

07:33 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

06:48 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -21.05% and 80.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

04:00 22 Mar 2023 ANAB

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.

08:17 22 Mar 2023 ANAB

AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?

AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

12:48 22 Mar 2023 ANAB

AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal

AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.

08:22 22 Mar 2023 ANAB

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events.

07:24 22 Mar 2023 ANAB

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference. The presentation will be available on Thursday, November 18, 2021, at 3:00 a.m. ET via https://wsw.com/webcast/jeff201/anab/1800252

03:06 22 Mar 2023 ANAB

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis

AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules.

ANAB Financial details

Company Rating
Buy
Market Cap
608.9M
Income
-128.72M
Revenue
10.29M
Book val./share
9.31
Cash/share
15.67
Dividend
-
Dividend %
-
Employees
102
Optionable
No
Shortable
Yes
Earnings
02 May 2023
P/E
-4.76
Forward P/E
-
PEG
-0.41
P/S
59.58
P/B
2.34
P/C
1.39
P/FCF
-8.22
Quick Ratio
16.94
Current Ratio
17.16
Debt / Equity
1.33
LT Debt / Equity
0.07
-
-
EPS (TTM)
-4.58
EPS next Y
-
EPS next Q
-0.63
EPS this Y
116.59%
EPS next Y
-
EPS next 5Y
-77.07%
EPS last 5Y
12.82%
Revenue last 5Y
15.52%
Revenue Q/Q
426.53%
EPS Q/Q
-20.34%
-
-
-
-
SMA20
-14.28%
SMA50
-21.26%
SMA100
-18.15%
Inst Own
100%
Inst Trans
0%
ROA
-21%
ROE
-44%
ROC
-0.2%
Gross Margin
12%
Oper. Margin
-1119%
Profit Margin
-1251%
Payout
-
Shs Outstand
27.93M
Shs Float
15.57M
-
-
-
-
Target Price
32
52W Range
18.2-32.435
52W High
-32%
52W Low
+20.89%
RSI
31.63
Rel Volume
0.64
Avg Volume
308.12K
Volume
196.45K
Perf Week
-2.73%
Perf Month
-15.72%
Perf Quarter
-15.33%
Perf Half Y
-10.97%
-
-
-
-
Beta
-0.101367
-
-
Volatility
0.52%, 1.6%
Prev Close
0.65%
Price
21.76
Change
-0.41%

ANAB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.20.32.752.30.37
Net income per share
-2.5-3.6-0.73-2.11-4.57
Operating cash flow per share
-1.97-2.57-0.52-1.67-2.61
Free cash flow per share
-2.01-2.6-0.54-1.67-2.63
Cash per share
17.3113.8314.4219.9815.67
Book value per share
19.7114.9714.5312.999.31
Tangible book value per share
19.7114.9714.5312.999.31
Share holders equity per share
19.7114.9714.5312.999.31
Interest debt per share
0.40.120.010.771.44
Market cap
1.57B439.71M586.99M953.23M872.83M
Enterprise value
1.47B270.07M336.88M479.96M820.98M
P/E ratio
-25.53-4.52-29.45-16.49-6.78
Price to sales ratio
314.7854.967.8315.0984.85
POCF ratio
-32.45-6.33-41.46-20.76-11.86
PFCF ratio
-31.75-6.25-39.86-20.77-11.8
P/B Ratio
3.241.091.482.673.33
PTB ratio
3.241.091.482.673.33
EV to sales
293.7133.764.497.679.81
Enterprise value over EBITDA
-24.52-2.82-17.39-8.4-7.8
EV to operating cash flow
-30.28-3.88-23.8-10.45-11.16
EV to free cash flow
-29.63-3.84-22.88-10.46-11.1
Earnings yield
-0.04-0.22-0.03-0.06-0.15
Free cash flow yield
-0.03-0.16-0.03-0.05-0.08
Debt to equity
0.050.070.050.81.33
Debt to assets
0.040.070.050.450.57
Net debt to EBITDA
1.761.7712.918.280.49
Current ratio
19.8912.7920.0134.417.16
Interest coverage
-40.39-103.2039.18-5.46
Income quality
0.790.710.710.790.57
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.112.010.250.343.56
Research and developement to revenue
11.2412.421.071.568.63
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.0400
Capex to revenue
-0.21-0.1-0.010-0.03
Capex to depreciation
-3.37-1.57-1.020.01-0.15
Stock based compensation to revenue
1.991.550.150.242.66
Graham number
33.2934.8115.4524.8230.93
ROIC
-0.24-1.390.270.16-0.25
Return on tangible assets
-0.12-0.22-0.05-0.09-0.21
Graham Net
16.412.7113.699.533.3
Working capital
412.38M348.2M376.74M537.78M421.15M
Tangible asset value
486.37M405.01M396.73M356.43M262.1M
Net current asset value
411.58M347.54M376.74M267.23M98.93M
Invested capital
0.020.0100.060.07
Average receivables
887.5K87K000
Average payables
3.88M10.84M10.23M2.98M2.26M
Average inventory
00000
Days sales outstanding
12.70000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
28.740000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.13-0.24-0.05-0.16-0.49
Capex per share
-0.04-0.03-0.020-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric History 2021-12-312022-03-312022-06-302022-09-30 2022-12-31
Revenue per share
0.040.040.040.050.24
Net income per share
-1.18-1.31-1.15-1.18-0.94
Operating cash flow per share
-0.92-0.76-0.86-0.63-0.38
Free cash flow per share
-0.87-0.76-0.86-0.63-0.39
Cash per share
19.9118.2415.6815.6615.67
Book value per share
12.9511.9310.799.819.31
Tangible book value per share
12.9511.9310.799.819.31
Share holders equity per share
12.9511.9310.799.819.31
Interest debt per share
0.760.920.930.920.84
Market cap
956.81M685.62M572.54M721.65M872.83M
Enterprise value
483.54M539.8M521.06M682.94M820.98M
P/E ratio
-7.35-4.73-4.4-5.39-8.26
Price to sales ratio
946.4706.82470.84558.12128.21
POCF ratio
-37.82-32.63-23.71-40.66-81.69
PFCF ratio
-39.98-32.54-23.63-40.55-80.37
P/B Ratio
2.682.071.882.63.33
PTB ratio
2.682.071.882.63.33
EV to sales
478.28556.5428.51528.19120.59
Enterprise value over EBITDA
-14.39-17.51-19.95-25.5-38.13
EV to operating cash flow
-19.11-25.69-21.58-38.48-76.83
EV to free cash flow
-20.2-25.62-21.51-38.37-75.6
Earnings yield
-0.03-0.05-0.06-0.05-0.03
Free cash flow yield
-0.03-0.03-0.04-0.02-0.01
Debt to equity
0.80.890.981.231.33
Debt to assets
0.450.470.50.550.57
Net debt to EBITDA
14.084.731.971.452.41
Current ratio
34.425.922.7921.3917.16
Interest coverage
21.49-6.54-4.74-4.83-6.11
Income quality
0.780.580.740.530.4
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
5.3310.526.726.851.38
Research and developement to revenue
26.4823.2117.1417.063.43
Intangibles to total assets
00000
Capex to operating cash flow
-0.050000.02
Capex to revenue
1.35-0.06-0.06-0.04-0.03
Capex to depreciation
3.55-0.1-0.14-0.09-0.29
Stock based compensation to revenue
3.937.985.484.850.98
Graham number
18.5518.7416.7416.1714.01
ROIC
0.09-0.11-0.06-0.06-0.06
Return on tangible assets
-0.05-0.06-0.05-0.05-0.04
Graham Net
9.57.655.083.643.3
Working capital
537.78M492.63M432.94M429.38M421.15M
Tangible asset value
356.43M330.75M304.31M277.62M262.1M
Net current asset value
267.23M217.99M153.27M109.56M98.93M
Invested capital
0.060.060.070.070.07
Average receivables
380.5K460.5K977K1.11M590K
Average payables
3.73M2.11M2.03M2.3M2.9M
Average inventory
00000
Days sales outstanding
085.4576.4682.130
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
01.051.181.10
Payables turnover
00000
Inventory turnover
00000
ROE
-0.09-0.11-0.11-0.12-0.1
Capex per share
0.05000-0.01

ANAB Frequently Asked Questions

What is AnaptysBio, Inc. stock symbol ?

AnaptysBio, Inc. is a US stock , located in San diego of Ca and trading under the symbol ANAB

Is AnaptysBio, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $32. The lowest prediction is $32 and the highest is $32

What is ANAB stock prediction ?

What is AnaptysBio, Inc. stock quote today ?

AnaptysBio, Inc. stock price is $21.76 today.

Is AnaptysBio, Inc. stock public?

Yes, AnaptysBio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap